Indaptus Therapeutics Gains Patent Approvals for Decoy Platform
Indaptus Therapeutics secures patents in China, Japan, and Israel for its Decoy platform targeting HBV and HIV treatments.
Overview of Patent Approvals
Indaptus Therapeutics, Inc. has announced the approval of new patents in China, Japan, and Israel for its Decoy platform. This platform utilizes Decoy bacteria compositions aimed at treating Hepatitis B virus (HBV) and human immunodeficiency virus (HIV). The patents cover combination therapies with both existing and investigational treatments, showcasing the company’s commitment to combating the global health challenges posed by these diseases. Dr. Michael Newman, Founder and Chief Scientific Officer, highlighted the importance of these approvals in maximizing the potential of their platform. The Decoy products activate the immune system and have demonstrated promising results in preclinical trials targeting both infectious diseases and cancer treatment. Indaptus aims to advance these innovative therapies while solidifying its leadership in the immunotherapy landscape.
Highlights of Recent Developments
Positive Aspects
- Indaptus has enhanced its intellectual property portfolio with new patent approvals in key international markets.
- The patents specifically address chronic Hepatitis B and HIV, targeting significant global health needs and expanding the possible market for these therapies.
- Preclinical studies reveal that the Decoy platform shows significant activity against chronic HBV and HIV, positioning Indaptus as an innovator in the field of immunotherapy.
- The company is moving patented candidates into clinical trial phases, paving the way for new treatments aimed at improving long-term patient outcomes.
Challenges Ahead
- Indaptus faces scrutiny due to its limited operating history, raising concerns about its ongoing viability.
- The company requires additional capital while lacking current cash flow, which could impede operations and growth.
- The clinical and preclinical development processes are lengthy and uncertain, presenting risks to the company’s future success and profitability.
Frequently Asked Questions
What recent patent approvals did Indaptus Therapeutics secure?
Indaptus secured patent approvals in China, Japan, and Israel for its Decoy platform targeting HBV and HIV treatments.
How does the Decoy platform work?
The Decoy platform uses attenuated and killed bacteria to stimulate the immune system against infections such as HBV and HIV.
What diseases are targeted by Indaptus’ new patents?
The patents cover the prevention and treatment of Hepatitis B virus (HBV) and human immunodeficiency virus (HIV).
What is the significance of these patents for Indaptus?
The patents reinforce Indaptus’ intellectual property and underscore the potential of its Decoy platform in tackling chronic infectious diseases.
What is the current status of Decoy20 clinical trials?
Decoy20 is currently undergoing a Phase 1 clinical trial in the U.S. for patients with advanced cancers.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$INDP Hedge Fund Activity
In recent activity, seven institutional investors have added shares of $INDP Stock to their portfolios, while seven have reduced their positions in the last quarter.
Here are some of the most significant movements:
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 17,829 shares (+inf%) in Q4 2024, totaling an estimated $15,013.
- TWO SIGMA SECURITIES, LLC added 16,620 shares (+inf%) in Q4 2024, totaling an estimated $13,995.
- CITADEL ADVISORS LLC removed 15,390 shares (-100.0%) in Q4 2024, for an estimated $12,959.
- GEODE CAPITAL MANAGEMENT, LLC added 8,989 shares (+12.3%) in Q4 2024, with an estimated value of $7,569.
- UBS GROUP AG added 2,001 shares (+383.3%) in Q4 2024, for an estimated $1,685.
- TOWER RESEARCH CAPITAL LLC (TRC) removed 1,299 shares (-27.0%) in Q4 2024, estimated at $1,093.
- RENAISSANCE TECHNOLOGIES LLC added 600 shares (+2.2%) in Q4 2024, with an estimated value of $505.
To track hedge funds’ Stock portfolios, explore Quiver Quantitative’s institutional holdings dashboard.
Full Release
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company committed to developing innovative treatments for cancer and viral infections, announced today it has secured new patent approvals in China, Japan, and Israel for its Decoy platform. These patents encompass the use of Decoy bacteria compositions aimed at preventing or treating Hepatitis B virus (HBV) and human immunodeficiency virus (HIV)—two diseases that continue to impose significant global health challenges. The patents also cover combination therapies with various approved and investigational treatments.
Dr. Michael Newman, Founder and Chief Scientific Officer of Indaptus, stated, “The allowance of these patents in key international markets underscores the potential of our Decoy platform in the fight against chronic infectious diseases. With millions of individuals impacted by HBV and HIV globally, the expansion of our intellectual property strengthens the novelty and therapeutic promise of our approach.”
A Growing Global Health Need
Chronic HBV infections remain a significant concern, especially in Asia.
- China has around 87 million individuals living with chronic HBV, making up nearly one-third of global cases.
- Japan has approximately 1.1 – 1.2 million people affected by chronic HBV.
- In 2022, HBV was responsible for about 1.1 million deaths globally, primarily due to cirrhosis and liver cancer.
Despite existing treatments, there is a pressing need for new therapies to enhance long-term outcomes.
A Unique Approach to Infectious Disease and Cancer Treatment
Preclinical studies have demonstrated that Indaptus’ Decoy bacteria—designed to stimulate the immune system—exhibit substantial activity against chronic HBV and HIV in standard models.
Patented candidates from the Decoy platform have also shown single-agent activity and durable, combination-mediated tumor eradication in various preclinical cancer models. One candidate, Decoy20, is currently under evaluation.
Indaptus Therapeutics Advances Immunotherapy with New Clinical Milestones
Indaptus Therapeutics is enhancing its role in the immunotherapy sector by advancing new treatments for both infectious diseases and cancer. Recently, the company reported progress in its Phase 1 clinical trial in the U.S. for patients suffering from advanced cancers.
Company Overview
Founded on over a century of immunotherapy research, Indaptus Therapeutics adopts a novel strategy. The company theorizes that effectively activating both innate and adaptive immune responses requires a multi-faceted set of signals that can be safely delivered through intravenous (i.v.) administration. Indaptus’ proprietary technology features single strains of attenuated and killed, non-pathogenic Gram-negative bacteria, designed to produce a multi-targeted platform of Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR), and Stimulator of interferon genes (STING) agonists.
The product candidates aim to minimize toxicity associated with i.v. use while maintaining their ability to prime and activate various immune pathways. Notably, the Decoy product candidates demonstrate antigen-agnostic capabilities, showing promise against metastatic pancreatic and colorectal cancers, breast carcinoma, and hepatocellular carcinoma in combinations with therapies such as anti-PD-1 checkpoint inhibitors and low-dose chemotherapy. Previous pre-clinical studies indicated that tumor elimination was achieved through innate and adaptive immune pathway activation following just one i.v. dose, notably facilitating a transition from “cold” to “hot” tumor inflammation signatures.
Additionally, IND-enabling nonclinical toxicology studies suggested that i.v. administration resulted in minimal cytokine release syndrome biomarkers due to the candidate’s propensity to target the liver, spleen, and tumors while being rapidly eliminated. Indaptus’ Decoy candidates also showed substantial single-agent activity against chronic hepatitis B virus (HBV) and human immunodeficiency virus (HIV) in pre-clinical models.
For further details, visit
www.indaptusrx.com
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act. These statements reflect management’s expectations and intentions, particularly regarding research and development plans. Such statements can be recognized by terms like “believe,” “expect,” “intend,” and others that suggest future outcomes that have yet to materialize.
Due to the nature of forward-looking statements, they are inherently subject to risks and uncertainties which may cause actual results to significantly differ from anticipated outcomes. Several factors can lead to this variance, such as limited operating history, challenges in raising necessary capital, lengthy clinical development processes, and the need for regulatory approvals. Additional risks include dependence on third parties for conducting preclinical studies and managing product candidates during clinical trials, potential delays caused by competitor products, and broader economic conditions affecting operations.
For a more comprehensive outline of these risks, please refer to the “Risk Factors” section in our Quarterly report on Form 10-Q for the quarter ending September 30, 2024, which was filed with the SEC on November 12, 2024, as well as our most recent Annual report on Form 10-K filed with the SEC on March 13, 2024. All forward-looking statements are qualified by these cautionary remarks, and the company does not undertake to update them unless required by law.
Contact Information:
Investor Relations:
CORE IR
Louie Toma
This article was initially published on Quiver News; read the full story for additional insights.
The views expressed in this article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
